China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
Culture Index
Score Breakdown
Relevance
14/25
Freshness
23/25
Authority
18/20
Brand Signal
12/15
Depth
4/15
5-Axis Cultural Radar
Chinese biotech deal making is moving beyond the licensing of individual drug candidates, as the country transforms from a follower to a global innovation leader, according to analysts. The latest transaction underscores that shift. Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharma